Associated Papers
Quantum mechanics as a tool to decipher the mutational landscape of human disease.
Zavitsanou EI et al.
Progress in Biophysics and Molecular Biology, 2026
Elucidating the role of the T790M mutation in BLU-945 selectivity for mutant EGFR: structural and energetic insights.
Tariq A et al.
Journal of Computer-aided Molecular Design, 2026
A multiplex, prime editing framework for identifying drug resistance variants at scale.
Abadie FMC et al.
Cell Genomics, 2026
TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Kobayashi K
Journal of Clinical Medicine, 2026
Recurrent Escape from Osimertinib-Induced Senescence Promotes Genomic Instability Associated with Therapeutic Resistance.
Mcdaid H et al.
Biorxiv : the Preprint Server for Biology, 2026
Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib.
Zhou M et al.
Npj Precision Oncology, 2026
Individualized management strategies for advanced non-small cell lung cancer with EGFR exon 19 deletion and L861Q compound mutations based on circulating tumor DNA monitoring: A case report.
Zhu X et al.
Oncology Letters, 2026
First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?
Abdayem P et al.
Drugs, 2026
Magnolol suppresses TKI-resistant EGFR-mutant lung cancer by inhibiting EGFR and AXL-cMyc.
Chen CC et al.
European Journal of Pharmacology, 2026
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis.
Bronte G et al.
Journal of Clinical Medicine, 2026
A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non-small cell lung cancer (NSCLC).
Du Y et al.
Science Advances, 2026
Furmonertinib in lung adenocarcinoma with EGFR exon 20 insertion mutation: A case report of positive outcome.
Wang Q et al.
Medicine, 2026
Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.
Xiang S et al.
Journal of Medicinal Chemistry, 2026
Integrated and Comprehensive Diagnostics: An Emerging Paradigm in Precision Oncology.
Das K et al.
Cancers, 2026
EGFR mutation spectrum and clinical correlations in Tunisian Non-Small cell lung cancer patients.
Abdelmaksoud-Dammak R et al.
Molecular Biology Reports, 2026
Endostar overcomes Osimertinib-resistance mediated EGFR-activation mutation, T790M and cis-C797S triple mutations via enhancing the binding of Osimertinib to EGFR protein.
Song Z et al.
Life Sciences, 2026
Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.
Wong AKQ et al.
Current Oncology (toronto, Ont.), 2026
Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting.
Damghani T et al.
Acs Medicinal Chemistry Letters, 2026
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel F et al.
Cancer Discovery, 2026
Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation.
Izumi H et al.
Cancer Treatment and Research Communications, 2026
Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.
Stewart HL et al.
Journal of Medicinal Chemistry, 2026
Synthesis and degradation effect of PROTACs targeting EGFR triple mutants.
Xi XX et al.
Bioorganic & Medicinal Chemistry, 2026
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Tomasini P et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2026
Clinical utility of pleural effusion supernatant cell-free DNA genotyping in previously treated patients with advanced non-small-cell lung cancer and disease progression: a multicenter retrospective study.
Chang SC et al.
Esmo Open, 2026
Illuminating the spectrum of genomic sequencing approaches in the precision oncology era: A UK perspective.
Rescigno P et al.
Cancer Treatment and Research Communications, 2026
Common epidermal growth factor receptor mutations in north Indian patients with non-small cell lung carcinoma: evidence from real-time polymerase chain reaction.
Behera R et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, 2025
Exon-level TP53 alterations and PD-L1 expression identified by pretreatment NGS stratify survival in EGFR-mutant non-small cell lung cancer treated with first-line osimertinib.
Kim SE et al.
Translational Lung Cancer Research, 2025
Dioxazolones as Masked Isocyanate Electrophiles for Global Profiling of Lysine Reactivity and Ligandability.
Feng Y et al.
Journal of the American Chemical Society, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Innovation in next-generation sequencing in non-small cell lung cancer diagnostics.
Scimone C et al.
Expert Review of Anticancer Therapy, 2025
Crossing barriers with CSF-based sequencing for leptomeningeal disease in EGFR mutant NSCLC.
Chugh B et al.
The Journal of Liquid Biopsy, 2025
Genetic composition and evolutionary trajectories of brain metastasis in non-small-cell lung cancer.
Nicoś M et al.
Lung Cancer (amsterdam, Netherlands), 2025
Tumor heterogeneity involving SCLC with a single exon deletion in RB1 and adenocarcinoma with EGFR-L718V mutation in EGFR-TKI-resistant lung cancer.
Kakuto S et al.
Lung Cancer (amsterdam, Netherlands), 2025
Cerebrospinal fluid ctDNA clarifies clonal divergence: leptomeningeal flare of EGFR-mutant disease after switch to selpercatinib for acquired RET fusion.
Kunimasa K et al.
The Journal of Liquid Biopsy, 2025
Prevalence and therapeutic response of EGFR T790I mutation in NSCLC patients with acquired resistance to EGFR-TKIs: a retrospective cohort study.
Shi J et al.
Bmc Cancer, 2025
PTPN9 dephosphorylates IGF1RY1165/1166 and alleviates IGF1R-mediated resistance to tyrosine kinase inhibitor in cholangiocarcinoma.
Hu JM et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2025
Topoisomerase IIb binding delineates localized mutational processes and driver mutations in cancer genomes.
Uusküla-Reimand L et al.
Nature Communications, 2025
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
Markovian state models uncover casein kinase 1 dynamics that govern circadian period.
Ricci CG et al.
Biophysical Journal, 2025
Comparison of the Efficacy of Different First-Line Therapies for EGFR L858R-Mutated NSCLC Patients With Brain Metastases.
Chen J et al.
Cancer Science, 2025
MUTE-Seq: An Ultrasensitive Method for Detecting Low-Frequency Mutations in cfDNA With Engineered Advanced-Fidelity FnCas9.
Ye S et al.
Advanced Materials (deerfield Beach, Fla.), 2025
Challenges associated with the treatment of E709K and L858R double mutation in lung adenocarcinoma: A case report and literature review.
Song J et al.
Oncology Letters, 2025
Comparison of somatic variant oncogenicity classification using ClinGen/CGC/VICC guidelines and QIAGEN Clinical Insight Interpret decision support software.
Goverdhan A et al.
Cancer Genetics, 2025